Mo1904 Efficacy and Safety of Vedolizumab in Elderly Patients with Inflammatory Bowel Disease

Navaneethan, Udayakumar; Kommaraju, Kiran kumar; Edminster, Timothy; Zhu, Xiang; Wilson, Kenneth A.; Glover, Sarah C.

doi:10.1016/s0016-5085(16)32746-9

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Safety outcomes were reported in 46 studies (Table S4) [ 13 , 18 , 20 , 26 , 27 , 31 , 32 , 37 , 38 , 41 , 42 , 45 , 46 , 55 , 56 , 59 , 61 , 64 , 65 , 68 , 70 – 74 , 78 – 80 , 84 , 89 , 94 , 97 , 102 , 104 , 105 , 107 , 109 ] over a vedolizumab exposure/follow-up period of 0.5–12 months (exposure/follow-up data available for 27 studies). Overall adverse event (AE) rates were reported in 23 studies (0–67% of patients; n = 2358) and infections in 12 studies (range 5–24%; n = 1176).…”

Section: Resultsmentioning

confidence: 99%

Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease

et al. 2018

View full text Add to dashboard Cite

BackgroundSelective patient recruitment can produce discrepancies between clinical trial results and real-world effectiveness.MethodsA systematic literature review and meta-analysis were conducted to assess vedolizumab real-world effectiveness and safety in patients with ulcerative colitis (UC) or Crohn’s disease (CD). MEDLINE, MEDLINE In-Process, EMBASE, and Cochrane databases were searched for real-world studies of vedolizumab in adult patients with UC/CD reporting clinical response, remission, corticosteroid-free remission, UC/CD-related surgery or hospitalization, mucosal healing, or safety published from May 1, 2014–June 22, 2017. Response and remission rates were combined in random-effects meta-analyses.ResultsAt treatment week 14, 32% of UC patients [95% confidence interval (CI) 27–39%] and 30% of CD patients (95% CI 25–34%) were in remission; and at month 12, 46% for UC (95% CI 37–56%) and 30% for CD (95% CI 20–42%). For UC, the rates of corticosteroid-free remission were 26% at week 14 (95% CI 20–34%) and 42% at month 12 (95% CI 31–53%); for CD they were 25% at week 14 (95%, CI 20–31%) and 31% at month 12 (95%, CI 20–45%). At month 12, 33–77% of UC and 6–63% of CD patients had mucosal healing. Nine percent of patients reported serious adverse events.ConclusionsVedolizumab demonstrated real-world effectiveness in patients with moderate-to-severely active UC or CD, with approximately one-half and one-third of patients, respectively, in remission at treatment month 12. These findings are consistent with clinical trial data and support the long-term benefit–risk profile of vedolizumab.Electronic supplementary materialThe online version of this article (10.1007/s00535-018-1480-0) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 99%

Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease

et al. 2018

View full text Add to dashboard Cite

show abstract

“…A single, multicentre, retrospective cohort study has reported on VDZ initiated over age 60 (mean 67.1) in 29 patients (10 UC and 19 CD) . Median treatment duration was 30 weeks.…”

Section: Vedolizumab In the Elderly Or Youngmentioning

confidence: 99%

Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease

Bye

Jairath

Travis

2017

Aliment Pharmacol Ther

103

View full text Add to dashboard Cite

Post-marketing data confirm the excellent safety of vedolizumab observed in registration trials. The signal of post-operative complications should be interpreted with caution, but warrants further study. Although comparative studies are needed, Vedolizumab may be a safe alternative in patients who best avoid systematic immunosuppression, including those pre-disposed to infection, malignancy or the elderly.

show abstract

“…Adverse events are more commonly reported in older patients. Postmarketing data identify events more commonly expected in this group, including pneumonia or death (48) Although safety cannot be confirmed, patients can be reassured that many patients have had normal pregnancies and that the benefits of breast feeding are likely to outweigh any risks.…”

Section: F Use In the Elderlymentioning

confidence: 99%

“…Most patients reporting AEs continued treatment. A single multicentre retrospective cohort study reported on vedolizumab initiated in patients over the age of 60 (mean 67.1 years) in 29 patients (10 UC, 19 CD)(48). Across six controlled trials, there were 27 pregnancies in female patients and 19 pregnancies in partners of male patients (49).…”

mentioning

confidence: 99%

Interfering with leukocyte trafficking in Crohn's disease

Biswas

Bryant

Travis

2019

Best Practice & Research Clinical Gastroenterology

View full text Add to dashboard Cite

Mo1904 Efficacy and Safety of Vedolizumab in Elderly Patients with Inflammatory Bowel Disease

Cited by 4 publications

References 0 publications

Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease

Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease

Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease

Interfering with leukocyte trafficking in Crohn's disease

Contact Info

Product

Resources

About